Vecta is developing VECAM, an enhanced action PPI, for the treatment
of nocturnal GERD symptoms, Erosive Esophagitis and peptic ulcers. VECAM is superior to the other
current PPI treatment regimemens in treating nocturnal GERD symptoms and as
a potent 24h gastric acid secretion inhibitor as of first treatment.
VECAM is administered at bedtime without food. VECAM is a PPI with robust
gastric acid reduction during the night and day with excellent patient compliance.
VECAM's Phase IIb clinical trial commenced on December 2009.
The use of already established compounds (drug repositioning approach1)
shortens the timeline of the drug development significantly.
We expect that our lead product will be launched by 2012.
1- Ashburn and Thor (2004) Nature 3:673-683